(Q35842270)

10 August 2017

1 reference

title

Clinical utility of current NNRTIs and perspectives of new agents in this class under development (English)

1 reference

10 August 2017

Zhijun Zhang

1

1 reference

10 August 2017

Robert Hamatake

series ordinal

2

1 reference

10 August 2017

Zhi Hong

series ordinal

3

1 reference

10 August 2017

publication date

1 May 2004

1 reference

Antiviral Chemistry & Chemotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

15

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

121-134

1 reference

Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Effect of human serum on the in vitro anti-HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Non-nucleoside reverse transcriptase inhibitors--an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Efficacy and Durability of Nevirapine in Antiretroviral-Experienced Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Clinical uses of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

A Pilot Study to Evaluate the Development of Resistance to Nevirapine in Asymptomatic Human Immunodeficiency Virus-Infected Patients with CD4 Cell Counts of >500/mm3 : AIDS Clinical Trials Group Protocol 208

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Lipodystrophy syndrome in patients with HIV infection: quality of life issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Delavirdine: a review of its use in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Efficacy of a nelfinavir- and nevirapine-containing salvage regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F095632020401500302

10.1177/095632020401500302

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference